Mirati lung cancer data disappoint, shares fall

 An experimental Mirati Therapeutics Inc (MRTX.O) drug that targets a specific genetic mutation shrank tumors in 44% of advanced lung cancer patients in clinical trials, but also caused serious side effects in 43% of them, the company said on Thursday.

https://www.reuters.com/business/healthcare-pharmaceuticals/mirati-drug-shrinks-tumors-44-advanced-lung-cancer-patients-2022-05-26/